-
Sarepta's Eteplirsen Receives Accelerated FDA Approval, Shares Soar 80%
Monday, September 19, 2016 - 10:18am | 318Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) soared more than 80 percent Monday morning after the U.S. Food and Drug Administration confirmed in a letter it granted the company with an accelerated approval for its Eteplirsen drug. Sarepta's drug is intended for the treatment of...
-
Why Did Sarepta Therapeutics Plunge 20%?
Thursday, June 2, 2016 - 11:26am | 347Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged more than 20 percent on Thursday after reports surfaced that the U.S. Food and Drug Administration may pressure the company to provide its Duchenne muscular dystrophy patients with at-cost access to its eteplirsen therapy on a "...
-
Sarepta Therapeutics Surges 20% On No News
Friday, May 20, 2016 - 7:51am | 339Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) were trading higher by 20 percent at one point early Friday morning on no confirmed news reports. Sarepta's investor relations website showed no new updates. Meanwhile, Twitter users were sharing various theories to explain the unexpected surge in...
-
Sarepta Spikes 20%, Feuerstein Says Company Can Win FDA Drug Approval
Thursday, April 28, 2016 - 11:15am | 278Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) spiked higher by around 20 percent Thursday morning after The Street's biotech expert Adam Feuerstein penned an article titled "Why Sarepta Can Ultimately Win FDA Drug Approval." Shares of Sarepta were hard hit after a federal...
-
The Street's Feuerstein Breaks Down Sarepta's 40% Plunge
Thursday, April 21, 2016 - 10:51am | 338Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged more than 40 percent on Thursday after the U.S. Food and Drug Administration released briefing documents which consisted of an updated clinical review of the company's Duchenne muscular dystrophy drug, eteplirsen. According to The...
-
Sarepta Therapeutics Gives Up Gains Following Notable Tweet
Tuesday, February 23, 2016 - 3:29pm | 313Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) spiked higher on heavy volume and hit an intra-day high of $15.74 Tuesday afternoon. Sarepta's gain was short-lived as the stock quickly gave up all gains and was trading lower by more than 2 percent mid-Tuesday afternoon. Investors and...
-
Investors Rewarded With Treats, Not Tricks, As Dow And S&P Close At Record Highs
Friday, October 31, 2014 - 4:54pm | 1361Read More...U.S. stocks surged on Friday, lifting the Dow and S&P 500 to new all-time high record closes. Investors were treated to news of a surprise stimulus expansion from the Bank of Japan. The Japanese central bank increased its yearly target for monetary expansion to 80-trillion yen ($724 billion...
-
Barron's Recap: Sunny Skies For Home Depot
Sunday, April 20, 2014 - 10:44am | 880Read More...This weekend in Barron's online: why it is time to buy Home Depot, the 100 best financial advisors in the United States, as well as the prospects for Raytheon, Sarepta, ClubCorp and more. Cover Story "Sunny Skies Over Home Depot" by Avi Salzman. As the housing market revives, shares of Home...
-
Market Wrap For January 16: Markets End Two Day Winning Streak
Thursday, January 16, 2014 - 5:46pm | 2518Read More...The market took a bit of a breather Thursday following two strong days of gains. Earnings from two major banks failed to keep the momentum alive and investors focused on Best Buy's (NYSE: BBY) disappointing holiday guidance which contradicts the strong retail sales report earlier this week....
